KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Long-Term Investments for 7 consecutive years, with $171.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 54.85% to $171.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $171.3 million through Dec 2025, down 54.85% year-over-year, with the annual reading at $171.3 million for FY2025, 54.85% down from the prior year.
  • Long-Term Investments hit $171.3 million in Q4 2025 for Royalty Pharma, up from $129.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $379.4 million in Q4 2024 to a low of $2.9 million in Q1 2021.
  • Historically, Long-Term Investments has averaged $221.5 million across 5 years, with a median of $215.7 million in 2021.
  • Biggest five-year swings in Long-Term Investments: plummeted 70.4% in 2021 and later soared 8207.91% in 2022.
  • Year by year, Long-Term Investments stood at $269.8 million in 2021, then crashed by 58.36% to $112.3 million in 2022, then surged by 77.56% to $199.5 million in 2023, then surged by 90.2% to $379.4 million in 2024, then plummeted by 54.85% to $171.3 million in 2025.
  • Business Quant data shows Long-Term Investments for RPRX at $171.3 million in Q4 2025, $129.4 million in Q3 2025, and $110.5 million in Q2 2025.